Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction
In the STEP-HFpEF Program, AF was observed in nearly one-half of patients with obesity-related HFpEF and was associated with several features of more advanced HF. Treatment with semaglutide led to significant improvements in HF-related symptoms, physical limitations, and exercise function, as well as reductions in weight, CRP, and NT-proBNP in people with and without AF and across AF types. The magnitude of semaglutide-mediated improvements in HF-related symptoms and physical limitations was more pronounced in those with AF vs without AF at baseline. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF; NCT04788511]; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM; NCT04916470]).
Authors
- Thomas Jensen
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Mark C. Petrie (ORCID: https://orcid.org/0000-0002-6333-9496)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- Barry A. Borlaug (ORCID: https://orcid.org/0000-0001-9375-0596)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Cecilia Rönnbäck
- Dalane W. Kitzman (ORCID: https://orcid.org/0009-0000-5274-0826)
- Melanie Jane Davies (ORCID: https://orcid.org/0000-0002-9987-9371)
- Béla Péter Merkely (ORCID: https://orcid.org/0000-0001-6514-0723)
- Evan L. O’Keefe (ORCID: https://orcid.org/0000-0002-2746-2323)
- Subodh Verma
- Søren Rasmussen
Institutions
- Semmelweis University (HU)
- Northwestern University (US)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- University of Leicester (GB)
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- Baylor Medical Center at Garland (US)
- Saint Luke's Hospital (US)
- Research Institute of Dallas (US)
- NIHR Leicester Biomedical Research Centre (GB)
- Wake Forest University (US)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.jacc.2024.08.023
- Citations
- 31
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 12.46
Funders
- U.S. Department of Defense
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Heart and Stroke Foundation of Canada
- Gilead Sciences
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- CSL Behring
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- LivaNova
- Amarin Corporation
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Arrowhead Pharmaceuticals
- Cytokinetics
- Prothena
- ReCor Medical
- Dexcom
- MyoKardia
- Tenax Therapeutics
- Impulse Dynamics
- Moderna
- Horizon Therapeutics
- National Institute for Health and Care Research
- British Heart Foundation
- Daiichi-Sankyo
- Novo Nordisk
- Astellas Pharma
- HLS Therapeutics
- Esperion Therapeutics
- National Institutes of Health
- American Regent
- Canadian Institutes of Health Research